A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib 100mg B.I.D. Versus Teriflunomide 14mg Q.D. in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-

Protocol No

NEURO-NOVARTIS-LOU064

Staff Member

Sam I Hooshmand

Phase

III

Summary

This study will compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis.

Objective

Remibrutinib vs Teriflunomide in Relapsing MS

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib 100mg B.I.D. Versus Teriflunomide 14mg Q.D. in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-label Remibrutinib